Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening programmes for foetomaternal alloimmune thrombocytopenia

L M Williamson1

  • 1University of Cambridge, Division of Transfusion Medicine, East Anglia Centre, Cambridge, UK. lorna.williamson@nbs.nhs.uk

Vox Sanguinis
|August 15, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Titmuss et al. Immune Activation Following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study. <i>Int. J. Mol. Sci.</i> 2023, <i>24</i>, 5869.

International journal of molecular sciences·2024
Same author

Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study.

International journal of molecular sciences·2023
Same author

Whole-genome and transcriptome analysis enhances precision cancer treatment options.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Transfusion in adults: 10-year survival of red cell, plasma and platelet recipients following transfusion.

Transfusion medicine (Oxford, England)·2016
Same author

Transfusion in children: epidemiology and 10-year survival of transfusion recipients.

Transfusion medicine (Oxford, England)·2016
Same author

A clinical governance framework for blood services.

Vox sanguinis·2015
Same journal

Barriers and enablers to non-remunerated plasma donation: A meta-synthesis of the qualitative literature using the theoretical domains framework.

Vox sanguinis·2026
Same journal

Haemolytic disease of the foetus and newborn due to anti-M: A systematic review.

Vox sanguinis·2026
Same journal

In vitro evaluation of apheresis platelet and plasma products collected and stored in non-DEHP disposable sets.

Vox sanguinis·2026
Same journal

Survey of national and regional rare donor programmes regarding Immunoglobulin A deficiency.

Vox sanguinis·2026
Same journal

Fibrinogen recovery in cryoprecipitate prepared from thawed plasma stored for 5 days post-thaw.

Vox sanguinis·2026
Same journal

Abstracts of the 39th International Congress of the ISBT, Kuala Lumpur, Malaysia, 20-24 June 2026.

Vox sanguinis·2026
See all related articles

Screening for Foetomaternal alloimmunisation to Human Platelet Alloantigens (FAIT) in pregnancy is not standard care. Further research is needed to improve FAIT screening and management, addressing current limitations in diagnostics and therapy.

Area of Science:

  • Reproductive immunology
  • Maternal-fetal medicine
  • Hematology

Background:

  • Foetomaternal alloimmunisation to Human Platelet Alloantigens (FAIT) can cause severe fetal thrombocytopenia.
  • Current screening for FAIT is not a standard obstetric care practice.
  • Antenatal screening offers potential for early intervention but faces challenges.

Purpose of the Study:

  • To assess existing FAIT screening strategies against World Health Organisation standards.
  • To identify knowledge gaps and research priorities in FAIT screening and management.
  • To evaluate the effectiveness and limitations of current diagnostic and therapeutic approaches.

Main Methods:

  • Review and analysis of current FAIT screening protocols and diagnostic assays.

Related Experiment Videos

  • Evaluation of existing literature on the relationship between alloantibodies and clinical outcomes.
  • Assessment of World Health Organisation screening program criteria.

    • Main Results:

    • Lack of reliable assays for platelet typing and antibody detection limits screening efficacy.
    • Limited understanding of alloantibody-disease correlation hinders accurate risk prediction.
    • Inability to non-invasively predict severe outcomes and controversy over optimal antenatal therapy remain significant barriers.

    Conclusions:

    • FAIT screening requires further development to meet established public health standards.
    • Research should focus on improving diagnostic accuracy, understanding disease pathogenesis, and optimizing antenatal interventions.
    • Standardization of FAIT screening and evidence-based therapeutic guidelines are crucial for improving fetal outcomes.